Connor, Clark & Lunn Investment Management (CC&L)’s CRISPR Therapeutics CRSP Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-49,068	Closed	-$3.21M	–	1257
2022 Q3	$3.21M	Buy	49,068 +36,857	+302%	+$2.67M	0.02%	406
2022 Q2	$742K	Sell	12,211 -21,110	-63%	-$1.24M	﹤0.01%	689
2022 Q1	$2.09M	Buy	+33,321	New	+$2.09M	0.01%	492
2021 Q4	–	Sell	-116,485	Closed	-$13M	–	1099
2021 Q3	$13M	Buy	116,485 +19,343	+20%	+$2.43M	0.07%	199
2021 Q2	$15.7M	Buy	97,142 +91,999	+1,789%	+$11.2M	0.08%	191
2021 Q1	$627K	Buy	+5,143	New	+$777K	﹤0.01%	762

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s CRSP Position: Q4 2022 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of CRISPR Therapeutics (CRSP) in Q4 2022, closing a stake of 49,068 shares — an estimated $3.21M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in CRSP in Q1 2021 and held it in 6 quarters. The position peaked at $15.7M in Q2 2021. 398 funds tracked by Wall St. Rank hold CRSP as of Q4 2022.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining CRISPR Therapeutics position as of Q4 2022 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 49,068 CRISPR Therapeutics shares in Q4 2022, an estimated $3.21M.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in CRISPR Therapeutics in Q1 2021 and held it in 6 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s CRISPR Therapeutics position peaked at $15.7M in Q2 2021.
398 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2022.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2022, filed 10 Feb 2023.